Naphtho-Gamma-Pyrones (NγPs) with Obvious Cholesterol Absorption Inhibitory Activity from the Marine-Derived Fungus Aspergillus niger S-48

Chang-Zheng Wu 1,†, Xiao-Ping Peng 1,†, Gang Li 1, Qi Wang 1 and Hong-Xiang Lou 1,2,*

1 Department of Natural Medicinal Chemistry and Pharmacognosy, School of Pharmacy, Qingdao University, Qingdao 266021, China; 2019026576@qdu.edu.cn (C.-Z.W.); pengxiaoping@qdu.edu.cn (X.-P.P.); gang.li@qdu.edu.cn (G.L.); wangqi@hmfl.ac.cn (Q.W.)
2 Key Laboratory of Chemical Biology of Ministry of Education, Department of Natural Product Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

* Correspondence: louhongxiang@sdu.edu.cn; Tel.: +86-531-8838-2012
† These authors contributed equally to this work.

Abstract: Eight naphtho-gamma-pyrones (NγPs) (1–8), together with four known biosynthetically related coumarin derivatives (9–12), were isolated from the potato dextrose agar media of a marine-derived fungus Aspergillus niger S-48. Among them, natural compounds 1 and 2 were tentatively subjected to benzohydrazide reaction to evaluate the importance of pyran rings in NγPs. Their structures were elucidated by extensive 1D and 2D NMR spectroscopic data and MS spectra. Compounds 1–4 showed obvious activity for reducing cholesterol absorption verging on ezetimibe. This work highlighted the potential of natural NγPs as NPC1L1 inhibitors.

Keywords: Aspergillus niger; natural products; naphtho-gamma-pyrones (NγPs); Niemann-Pick C1-Like 1; cholesterol

1. Introduction

Marine fungi with unique metabolic mechanisms under hypersaline, hyperbaric, and oligotropic conditions have provided structurally diverse and pharmacologically active secondary metabolites [1–3]. Among them, Aspergillus niger was one of the most-found marine fungal species [4], and biosynthesized a number of specialized small molecules, such as naphtho-gamma-pyrones (NγPs), ochratoxins, fumonisins, bicoumarins, malformins, and asperazines [5]. Particularly, NγPs pigments were extensively isolated as antimicrobial, antiviral, and antioxidant agents, attracting a lot of attention from chemists and biologists [6–10].

In our continuing isolation on marine-derived fungi [3], an Aspergillus species, A. niger S-48, was obtained, and was subjected to chemical investigation to pursue biologically active NγPs pigments. As expected, twelve secondary metabolites (Figure 1), including eight known NγPs, were finally isolated from A. niger S-48. Following the established bioassay approaches in our laboratory, these isolates were evaluated for antibacterial, antifungal, cytotoxic, and quorum-sensing inhibitory activity, and cholesterol absorption inhibition activities. In order to tentatively evaluate the importance of pyran ring in NγPs for bioactivity, two compounds with enough amounts were modified for bioassay. Herein, the detailed isolation, identification, and bioactivities of natural or semisynthetic compounds are described.
2. Experimental Section

2.1. General Experimental Procedures

HRESIMS data were obtained on an LTQ-Orbitrap spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an ESI source. NMR spectra were measured on Bruker Advance 500 MHz and JEOL JNM-ECP 600 MHz spectrometers. Optical rotations...
were measured on a PerkinElmer 241MC polarimeter (PerkinElmer Instruments, Norwalk, CT, USA) in MeOH at 20 °C. Electronic circular dichroism (ECD) spectra were acquired on a Chirascan spectropolarimeter (Applied Photophysics, Leatherhead, UK). Column chromatography (CC) was equipped with silica gel (200–300 mesh; Qingdao Haiyang Chemical Co., Ltd., Qingdao, China). Thin-layer chromatography (TLC) was performed with silica gel GF254 plates (Qingdao Haiyang Chemical Co., Ltd., China). Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf 200 system equipped with a C18 spherical column (20–35 µm, 100 Å, 80 g). The semi-preparative high-performance liquid chromatography (HPLC) system (Agilent 1260 Infinity II; Agilent technologies, Böblingen, Germany) was equipped with a 1260 Quat Pump VL, a 1260 Vialsampler, a 1260 MCT, a 1260 DAD WR, and a ZORBAX SB-C18 column (5 µm, 10.0 × 250 mm), and a π NAP COSMOSIL Packed Column (5 µm, 10.0 × 250 mm).

2.2. Strain and Culturing Conditions

The fungal strain *A. niger* S-48 was isolated from the root of the mangrove plant, *K. candel* (L.) Druce, collected from the Beibu Bay of Guangxi Province, China. The fungus was identified according to its morphological characteristics and 18S rRNA sequences (Figure S1 from Supplementary Materials; GenBank No. MZ573243). The fungus was deposited at the School of Pharmacy, Qingdao University, China, and was maintained at −80 °C. For large-scale fermentation, the fresh mycelia of *A. niger* S-48 were cultured on potato dextrose agar (PDA) media at 28 °C for 4 days. The agar plugs were cut into small pieces under aseptic conditions and 100 pieces were used to inoculate 100 flasks (1L) of PDA media, each containing potato extract powder 0.9 g, glucose 3.0 g, sea salt 4.5 g, agar 3.0 g, and distilled water 0.15 L at pH 5.6. The cultures were grown under static conditions at 28 °C for 40 days.

2.3. Extraction and Purification

The fermented cultures were extracted by ethyl acetate (EtOAc) three times. The merged organic phase was dried in vacuo to yield the crude extract (5.6 g). The crude extract was subjected to column chromatography on silica gel with a gradient of MeOH/CH2Cl2 system (0/100, 1/99, 2/98, 3/97, 4/96, 5/95, 1/10, 1/9, 1/8 and 1/6, v/v) to obtain six fractions (Fr.A–Fr.F) based on TLC technology. Fr.C (1.5 g) was fractionated through a CombiFlash Rf 200 purification system, eluting with MeOH-H2O (50% MeOH for 40 min, 70% MeOH for 40 min, 100% MeOH for 40 min) to obtain four subfractions (Fr.C1–Fr.C4). Fr.C2 (170.0 mg) was separated by semi-preparative HPLC system (MeOH/H2O, 50/50, 2 mL/min) using a ZORBAX SB-C18 column to give compounds 9 (9.5 mg, \( t_R 12.5 \) min), 10 (2.5 mg, \( t_R 14.7 \) min), 11 (3.3 mg, \( t_R 22.2 \) min), and 12 (14.0 mg, \( t_R 32.8 \) min). Fr.C3 (500.0 mg) was purified by a semi-preparative HPLC system (MeOH/H2O, 90/10, 2 mL/min) using a C18 YMC-Pack ODS-A column to afford compounds 6 (27.0 mg, \( t_R 17.0 \) min) and 7 (20.0 mg, \( t_R 18.4 \) min). Fr.C4 (350.0 mg) was loaded onto Sephadex LH-20 column eluting with MeOH/CH2Cl2 (2/1) to obtain four fractions (Fr.C1–Fr.C4). Following a similar measure, the Fr.C4 (300.0 mg) was further purified by a semi-preparative HPLC system (CH3CN/H2O, 65/35, 2 mL/min) using a π NAP COSMOSIL Packed Column to obtain compounds 1 (7.2 mg, \( t_R 26.2 \) min), 2 (21.5 mg, \( t_R 29.8 \) min), 3 (5.4 mg, \( t_R 31.6 \) min), 4 (3.5 mg, \( t_R 37.9 \) min), 5 (2.6 mg, \( t_R 24.5 \) min), and 8 (8.0 mg, \( t_R 18.3 \) min).

2.4. Structural Modification

Hydrazine monohydrate (3.75 µL, 0.12 mmol) was joined in a solution of compound 1 (7 mg, 0.012 mmol) in absolute ethanol (5 mL), and then the mixture was stirred for eight hours under 90 °C reflux, with TLC analysis indicating the consumption of the starting material. After reaction, water (5 mL) was added to terminate the reaction. The solution was evaporated slowly in vacuo and was further extracted with ethyl acetate (3 × 5 mL). The organic phase was washed with brine and dried with sodium sulfate,
filtered, and concentrated slowly using rotary evaporation. The mixture was purified by a semi-preparative HPLC system (CH$_3$CN/H$_2$O, 80/20, 2 mL/min) using a C18 YMC-Pack ODS-A column to obtain semisynthetic compound 13 (2.1 mg, 30.0% yield, ≥98%). A similar reaction approach was applied to compound 2 to obtain the derivative 14 (Figure S2 from Supplementary Materials).

Compound 13: brown powder; $^1$H NMR (DMSO-d$_6$, 600 MHz), and $^{13}$C NMR (DMSO-d$_6$, 150 MHz), see Table S1 from Supplementary Materials; positive HRESIMS m/z [M + H]$^+$ 585.1865 (calcd for C$_{32}$H$_{29}$N$_2$O$_9$, 585.1868) see Figure S11 from Supplementary Materials.

Compound 14: brown powder; $^1$H NMR (DMSO-d$_6$, 600 MHz) and $^{13}$C NMR (DMSO-d$_6$, 150 MHz) see Table S2 from Supplementary Materials; positive HRESIMS m/z [M + H]$^+$ 585.1870 (calcd for C$_{32}$H$_{29}$N$_2$O$_9$, 585.1868) see Figure S16 from Supplementary Materials.

2.5. Molecular Docking Methods

The molecular docking was carried out according to the previously described approach [11]. In general, it was carried out by SYBYL-X 2.0. The ligand molecule was drawn using the standard parameters of SYBYL-X. Their geometric conformations were energy-minimized further by employing the Tripos force field for 1000 steps, and Gasteiger–Hückel charges were calculated. The protein receptor was prepared using the standard method. PyMOL was used as a viewer for interaction between ligands and the protein receptor.

2.6. Inhibition of Cholesterol Absorption

Cholesterol uptake in Caco-2 cells was performed according to a previously reported method [12,13]. Caco-2 cells were received from the American Type Culture Collection (Rockvill, MD) (ATCC®-HTB-37™). Samples in DMSO were dissolved in cell-culture medium and diluted to a concentration of 100 µM. Ezetimibe (100 µM) was used as a positive control for this study. The fluorescence was measured at the excitation wavelength of 485 nm and emission wavelength of 535 nm. BCA kit (Thermo Fisher Scientific, Waltham, MA, USA) was used to determine protein concentration with bovine serum albumin as standard. The whole protein represented the total number of cells used for normalization. The effects were expressed as the percentage of cholesterol uptake corresponding to the control values.

2.7. Antimicrobial Activities

Bacterial and fungal pathogens (Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus subtilis, Escherichia coli, Candida albicans, Fusarium foetens, F. solanum, F. mangiferae, F. oxysporum f. sp. cubense, F. graminearum, Colletotrichum musae (ACCC 31244), C. coccoidea (ACCC 36067), C. asiaticum, Cucumber fusarium wilt, Cowpea wilt, Nectria sp., and Alternaria solani) were used to assess the antimicrobial activities of compounds. Antimicrobial activity was carried out by the paper-agar disk diffusion assay as in the previously reported method [14]. Samples were dissolved in MeOH and diluted to a concentration of 4 mg/mL. Next, 10 µL of the sample solutions was dropped into 6 mm sterile filter paper disks, and the filter paper disks were placed evenly on the solid media with test strains [14]. Streptomycin, actidione, and fluconazole were used as the positive controls, and MeOH was used as the blank control. Antimicrobial activity was evaluated by the diameter of inhibitory zones in the solid media.

3. Results and Discussion

3.1. Identification of Metabolites

The structures of compounds 1–12 (Figure 1), including eight known NγPs, fonsecinone A (1) [15], aurasperone A (2) [15], asperpyrones B and C (3 and 4) [16], rubasperone B (5) [17], aurasperone E (6) [18], fonsecinone C (7) [18], and flavasperone (8) [19], as well as four known coumarins, orlandin (9) [16], 4,7-dimethoxy-5-methylcoumarin (10) [20], 7-hydroxy-4-methoxy-5-methylcoumarin (11) [21], and desmethylykotanin (12) [22], were identified by comparing their NMR data and MS spectra with previously reported data.
The ECD spectra of compounds 1–4 (see Figures S53 and S54) indicated that the absolute configurations of compounds 1–4 were (R), which was consistent with the previously reported data [18]. Specifically, compounds 1–8 are NγPs compounds, which were previously isolated from Aspergillus spp. The structures of NγPs consist of both naphthalene and γ-pyrene moiety, and there are monomeric and dimeric forms [23]. Moreover, compounds 1 and 2 displayed antibacterial activities against Helicobacter pylori [16]. The biological activity of NγPs is inextricably linked to its structure. The radical scavenging potential of NγPs is related to the number of hydroxyl substitutes on the skeleton [8], and the phytotoxicity of NγPs is connected to the γ-pyrene ring [24]. Compounds 9–12 are coumarin derivatives, and they had shown antibacterial and antifungal activities [7].

3.2. Modification and Identification of Semisynthetic NγPs

In order to evaluate the importance of the pyran ring in NγPs on bioactivity, compounds 1 and 2 were tentatively modified based on a benzohydrazide reaction [25]. Nucleophlic attack of hydrazine at C-2 of the NγP, followed by ring opening, further nucleophilic attack of the second nitrogen atom at the carbonyl carbon, and subsequent dehydration led to the formation of the pyrazole ring (Figure S3 from Supplementary Materials). Finally, compounds 13 and 14 were obtained as the corresponding semisynthetic products consisting of the partial NγP and the pyrazole ring (Figure 1).

Compound 13 was obtained as a brown powder. Its molecular formula was determined to be C_{32}H_{26}N_{2}O_{6} on the basis of HRESIMS analysis, indicating twenty degrees of unsaturation. Compared to compound 1, the molecular weight of compound 13 went up by 14 amu. Therefore, only one pyrone site of bis-NγPs was subjected to reaction. Specifically, the unreacted pyrone was confirmed by detailed analysis of 1H and 13C NMR data, such as C-9 (δC 119.7), together with the key HMBC correlation signals (Figure S4 from Supplementary Materials) from H-7 (δH 7.24) to C-9/C-10a (δC 107.4), from H-6 (δH 7.10) to C-4a (δC 108.3)/C-7 (δC 101.7), and from H-3 (δH 6.52) to C-2 (δC 168.1)/C-4a. The key HMBC correlation signals (Figure S4 from Supplementary Materials) of 3H-14' (δH 2.35) with C-4' (δC 105.9)/C-5'/ (δC 138.7), and of H-4' (δH 6.93) with C-3' (δC 148.5)/C-5', indicated compound 13 was a pyrazole-type compound. Thus, the structure of semisynthetic compound 13 was determined.

Compound 14 was obtained as a brown powder and had the same molecular formula C_{32}H_{26}N_{2}O_{6} as 13 from the HRESIMS analysis. It showed that the semisynthetic compound 14 contained a pyrazole ring. This was validated by key HMBC correlation (Figure S5 from Supplementary Materials) signals from 3H-14' (δH 2.34) to C-4' (δC 105.9)/C-5' (δC 138.7), and from H-4' (δH 6.92) to C-3' (δC 148.6)/C-5'. Similarly, the unreacted pyrone was detected through detailed analysis of 1H and 13C NMR data, such as C-7 (δC 120.1), together with the key HMBC correlation signals (Figure S5 from Supplementary Materials) of H-9 (δH 7.27) with C-5a (δC 110.7)/C-7, of H-10 (δH 7.37) with C-5a/C-9 (δC 101.8), and of H-10 with C-4 (δC 184.1). Therefore, the structure of compound 14 was determined.

3.3. Biological Activities

Niemann-Pick C1-Like 1 (NPC1L1) is a key target involving cholesterol cellular uptake [13]. Both compounds 1–4 and 9–14 were tested for cholesterol absorption inhibition activity [26]. Compounds 1–4 showed similar inhibitory activity in 100 μM compared with ezetimibe, the only FDA-approved NPC1L1 inhibitor (Figure 2) [12]. The results showed that compound 4 had the highest inhibitory activity for reducing cholesterol absorption among all compounds, and deserves further evaluation. The reason for the function of NγPs may be related to the pyrones site. To elucidate the binding mechanism of compound 4 and NPC1L1, molecular docking was performed to predict the binding mode of compound 4. Interestingly, Lys1027 and Phe532 were involved in the formation of hydrogen bonds with NγPs (Figure 3). In addition, compound 4 and Phe532 interacted by π–π stacking, which further increased the affinity of compound 4 with NPC1L1. Through decreasing cholesterol absorption with a NPC1L1 inhibitor, ezetimibe was the first and only inhibitor approved
for the treatment of hypercholesterolemia for nearly 20 years [12]. Natural products from marine fungi could be assumed to obtain NPC1L1 potential inhibitors.

![Figure 2](image2.png)

**Figure 2.** Compounds 1–4 and 9–14 at the concentration of 100 µM, the rate of inhibition of cholesterol esterase. Ezetimibe was used as a positive control.

![Figure 3](image3.png)

**Figure 3.** The binding mode of compound 4 with NPC1L1. Compound 4 was shown in cyan. The figure was produced with PyMOL. The related amino acids were shown in yellow.

The antimicrobial activities of all fourteen compounds, including eight NγPs, four coumarins, and two semisynthetic compounds, were evaluated by the paper-agar disk-diffusion methods. However, none of them showed activities against test pathogens, including Gram-positive and Gram-negative bacteria.
4. Conclusions

In summary, this study describes the isolation, identification, cholesterol absorption inhibition activity, and antimicrobial activity of NγPs and coumarins from the marine-derived fungus *A. niger* S-48. Their structures were identified by 1D and 2D NMR spectroscopic data and MS analysis. In addition, the reaction of natural NγPs with hydrazine afforded two semisynthetic compounds, containing naphtho-gamma-pyrones and the pyrazole ring. It has to be noted that benzohydrazide reaction was rarely reported on NγPs. All isolated or semisynthetic compounds had no effects during the assays of antimicrobial activities. Notably, compound 4, as one of the isolated NγPs, showed activity for reducing cholesterol absorption comparable to the positive drug ezetimibe. As far as we know, this is the first report to curb cholesterol cellular uptake activity using NγPs. Therefore, we obtain NγPs as potential NPC1L1 inhibitors, which call for further research.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27082514/s1, Figures S1–S57; Tables S1–S5. NMR data, NMR spectra, HRESIMS of compounds 13 and 14. NMR data, NMR spectra, HRESIMS or ESIMS of compounds 1–12. Experimental ECD spectra and optical rotations of compounds 1–4.

Author Contributions: Writing—original draft preparation, C.-Z.W. and X.-P.P.; writing—review and editing, G.L. and Q.W.; funding acquisition, H.-X.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China [grant numbers 41706077, 81903494, and 41906030], and China Postdoctoral Science Foundation [grant number 2019M652309].

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the authors.

References
1. Sutak, R.; Camadro, J.M.; Lesuisse, E. Iron uptake mechanisms in marine phytoplankton. *Front. Microbiol.* 2020, 11, 566691. [CrossRef] [PubMed]
2. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* 2014, 31, 160–258. [CrossRef] [PubMed]
3. Zhang, H.M.; Ju, C.X.; Li, G.; Sun, Y.; Peng, Y.; Li, Y.X.; Peng, X.P.; Lou, H.X. Dimeric 1,4-benzoquinone derivatives with cytotoxic activities from the marine-derived fungus *Penicillium* sp. L129. *Mar. Drugs* 2019, 17, 383. [CrossRef] [PubMed]
4. Anh, C.V.; Kang, J.S.; Choi, B.-K.; Lee, H.-S.; Heo, C.-S.; Shin, H.J. Polyketides and meroterpenes from the marine-derived fungi *Aspergillus unguis* 158SC-067 and *A. flocculosus* 01NT-1.5 and their cytotoxic and antioxidant activities. *Mar. Drugs* 2021, 19, 415. [CrossRef]
5. Lee, Y.M.; Kim, M.J.; Li, H.; Zhang, P.; Bao, B.; Lee, K.J.; Jung, J.H. Marine-derived *Aspergillus* species as a source of bioactive secondary metabolites. *Mar. Biotechnol.* 2013, 15, 499–519. [CrossRef]
6. Lund, N.A.; Robertson, A.; Whalley, W.B. The chemistry of fungi. Part XXI.* asperxanthone and a preliminary examination of aspergillin. J. Chem. Soc. 1953, 3, 2434–2439. [CrossRef]
7. Nielsen, K.F.; Mogensen, J.M.; Johansen, M.; Larsen, T.O.; Frisvad, J.C. Review of secondary metabolites and mycotoxins from the *Aspergillus niger* group. *Anal. Bioanal. Chem.* 2009, 395, 1225–1242. [CrossRef]
8. Carboue, Q.; Maresca, M.; Herbette, G.; Roussos, S.; Hamrouni, R.; Bombarda, I. Naphtho-gamma-pyrones produced by *Aspergillus tubingensis* G131: New source of natural nontoxic antioxidants. *Biomolecules* 2020, 10, 29. [CrossRef]
9. Cai, X.; Yu, H.; Yu, Y.; Li, Q.; Chen, B.; Huang, Y.; Zou, X.; Huang, B.; Tang, J. Separation of five naphtho-gamma-pyrones from pleurotus ostreatus by high-speed countercurrent chromatography. *J. Sep. Sci.* 2018, 41, 4551–4558. [CrossRef]
10. Xiao, J.; Zhang, Q.; Gao, Y.Q.; Shi, X.W.; Gao, J.M. Antifungal and antibacterial metabolites from an endophytic *Aspergillus* sp. associated with *Melia azedarach*. *Nat. Prod. Res.* 2014, 28, 1388–1392. [CrossRef] [PubMed]
11. Zhang, R.; Song, Z.; Wang, X.; Xue, J.; Xing, D. One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1. *Eur. J. Med. Chem.* 2021, 216, 113358. [CrossRef] [PubMed]
12. Zhang, R.; Liu, W.; Zeng, J.; Meng, J.; Jiang, H.; Wang, J.; Xing, D. Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption. *Eur. J. Med. Chem.* 2022, 230, 114111. [CrossRef] [PubMed]

13. Alltman, S.W.; Davis, H.R.; Zhu, L.; Yao, X.; Hoos, L.M.; Tetzloff, G.; Iyer, S.N.; Maguire, M.; Golovko, A.; Zeng, M.; et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. *Science* 2004, 303, 1201–1204. [CrossRef] [PubMed]

14. Chen, L.; Wang, N.; Wang, X.; Hu, J.; Wang, S. Characterization of two anti-fungal lipopeptides produced by *Bacillus amyloliquefaciens* SH-B10. *Bioresour. Technol.* 2010, 101, 8822–8827. [CrossRef]

15. Hua, Y.; Pan, R.; Bai, X.; Wei, B.; Chen, J.; Wang, H.; Zhang, H. Aromatic polyketides from a symbiotic strain *Aspergillus fumigatus* D and characterization of their biosynthetic gene D8.t287. *Mar. Drugs* 2020, 18, 324. [CrossRef]

16. Han, J.; Yang, N.; Wei, S.; Jia, J.; Lin, L.; Li, J.; Bi, H.; Song, F.; Xue, X. Dimeric hexylitaconic acids from the marine-derived fungus *Aspergillus amyloliquefaciens* CUGBMF180262. *Nat. Prod. Res.* 2020, 36, 578–585. [CrossRef]

17. Huang, H.B.; Feng, X.J.; Liu, L.; Chen, B.; Lu, Y.J.; Ma, L.; She, Z.G.; Lin, Y.C. Three dimeric naphtho-γ-pyrone from the mangrove endophytic fungus *Aspergillus tubingensis* isolated from *Pongamia pinnata*. *Plant Med.* 2010, 76, 1888–1891. [CrossRef]

18. He, Y.; Tian, J.; Chen, X.; Sun, W.; Zhu, H.; Li, Q.; Lei, L.; Yao, G.; Xue, Y.; Wang, J.; et al. Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens. *Sci. Rep.* 2016, 6, 24291. [CrossRef]

19. Kouipou Toghueo, R.M.; Kemgne, E.A.M.; Sahal, D.; Yadav, M.; Kenou Kagho, D.U.; Yang, B.; Baker, B.J.; Boyom, F.F. Specialized antiplasmodial secondary metabolites from *Aspergillus niger* 58, an endophytic fungus from *Terminalia catappa*. *J. Ethnopharmacol.* 2021, 269, 113672. [CrossRef]

20. Li, Y.; Wang, S.F.; Zhao, Y.; Liu, K.C.; Wang, X.M.; Yang, Y.P.; Li, X.L. Chemical constituents from *Clematis delavayi* var. *spinescens*. *Molecules* 2009, 14, 4433–4439. [CrossRef]

21. Ur Rehman, N.; Halim, S.A.; Khan, M.; Hussain, H.; Yar Khan, H.; Khan, A.; Abbas, G.; Rafiq, K.; Al-Harrasi, A. Antiproliferative and carbonic anhydrase II inhibitory potential of chemical constituents from *Lycium shawii* and *Aloe vera*: Evidence from in silico target fishing and in vitro testing. *Pharmaceuticals* 2020, 13, 94. [CrossRef] [PubMed]

22. Gilchrist, C.L.M.; Lacey, H.J.; Vuong, D.; Pitt, J.I.; Lange, L.; Lacey, E.; Pilgaard, B.; Chooi, Y.H.; Piggott, A.M. Comprehensive chemotaxonomic and genomic profiling of a biosynthetically talented Australian fungus, *Aspergillus burnetti* sp. nov. *Fungal Genet. Biol.* 2020, 143, 103435. [CrossRef] [PubMed]

23. Lu, S.; Tian, J.; Sun, W.; Meng, J.; Wang, X.; Fu, X.; Wang, A.; Lai, D.; Liu, Y.; Zhou, B. Bis-naphtho-γ-pyrones from fungi and their bioactivities. *Molecules* 2014, 19, 7169–7188. [CrossRef] [PubMed]

24. Sun, W.; Wang, A.; Xu, D.; Wang, W.; Meng, J.; Dai, J.; Liu, Y.; Lai, D.; Zhou, L. New ustilaginoidins from rice false smut balls caused by *Villosiclava virens* and their phytotoxic and cytotoxic activities. *J. Agric. Food Chem.* 2017, 65, 5151–5160. [CrossRef]

25. Solis, C.M.; Salazar, M.O.; Ramallo, I.A.; Garcia, P.; Furlan, R.L.E. A tyrosinase inhibitor from a nitrogen-enriched chemically engineered extract. *ACS Comb. Sci.* 2019, 21, 622–627. [CrossRef] [PubMed]

26. Thilavech, T.; Adisasawattana, S. Cyanidin-3-rutinoside acts as a natural inhibitor of intestinal lipid digestion and absorption. *BMC Compl. Altern. Med.* 2019, 19, 242. [CrossRef]